Forward-looking statements This announcement contains or may contain forward-looking statements concerning Polyus and/or Polyus group. Generally, the words will , may , should , could , would , can , continue , opportunity , believes , expects , intends , anticipates , estimates or similar expressions identify forward-looking statements. The forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed in the forward-looking statements. Forward-looking statements include statements relating to future capital expenditures and business and management strategies and the expansion and growth of Polyus and/or Polyus group s operations. Many of these risks and uncertainties relate to factors that are beyond Polyus and/or Polyus group s ability to control or estimate precisely and therefore undue reliance should not be placed on such statements which speak only as at the date of this announ
Regulatory News: Celyad Oncology SA (Brussels:CYAD) (Paris:CYAD) (NASDAQ:CYAD) (Euronext Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of chimeric
Search jobs 19-Jan-2021 Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Genmab Announces that Janssen has been Granted U.S. FDA Approval for DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
Company Announcement
®
(daratumumab and hyaluronidase-fihj) approved by U.S. FDA as the first and only therapy for newly diagnosed Light-chain (AL) amyloidosis
Accelerated approval of DARZALEX
Genmab to receive USD 30 million milestone payment on first commercial sale
Copenhagen, Denmark; January 15, 2021 – Genmab A/S (Nasdaq: GMAB) announced today that the U.S. Food and Drug Administration (U.S. FDA) has approved the use of DARZALEX
Celyad Oncology Presents Data Update from Phase 1 alloSHRINK Trial for CYAD-101 in mCRC at ASCO-GI Symposium
January 18, 2021 01:00 ET | Source: Celyad Oncology SE Celyad Oncology SE Mont-Saint-Guibert, BELGIUM
Median overall survival and median progression free survival from the dose-escalation segment of the trial were 10.6 months and 3.9 months, respectively
Tumor burden decrease observed in eight of 15 refractory unresectable mCRC patients, including six of nine patients at the highest dose level of 1x10
9 cells per infusion
Emergence of new T cell clones in the peripheral blood T cell repertoire four months after therapy was observed in patients analyzed from the highest dose level who experienced either a confirmed partial response or stable disease suggesting that modulation of the endogenous immune response may be an important mechanism of action of CYAD